This concept has been translated to the clinic, and an ongoing first-in-human phase I clinical trial of MOv18 IgE targeting folate receptor-alpha (FRα) (NCT02546921, www.clinicaltrials.gov) recently reported promising interim data in patients with ovarian cancer [10]. Here, IGHE is linked to ovarian carcinoma.